1515 South Federal Highway Suite 207
33432 Boca Raton FL, ae
Kewin Mc Knight
+1 (800) 404-8982
Nutra Pharma CEO, Rik J. Deitsch, has published a letter to Shareholders outlining the current efforts and the future goals of the Company
"We have been very busy here at Nutra Pharma," explained Rik J. Deitsch , Chairman and CEO of Nutra Pharma Corporation. "I wanted to take this opportunity to outline the progress that we've made and the timeline for our future efforts moving into 2012 and beyond," he concluded.
Nutra Pharma currently produces three drugs for the treatment of pain: Cobroxin ® , an over-the-counter pain reliever designed to treat moderate to severe (Stage 2) chronic pain; as well as Nyloxin (TM) and Nyloxin (TM) Extra Strength, stronger versions of Cobroxin ® . These products are currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress.
The Shareholder Letter is available on the Company's website at: http://www.nutrapharma.com/4Q11_shareholder_letter.pdf
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin(TM) . For additional information about Nutra Pharma, visit: http://www.NutraPharma.com
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an firstname.lastname@example.org.